PL3435980T3 - Fizjologicznie zrównoważone preparaty fosnetupitantu do wstrzykiwania - Google Patents
Fizjologicznie zrównoważone preparaty fosnetupitantu do wstrzykiwaniaInfo
- Publication number
- PL3435980T3 PL3435980T3 PL17729822T PL17729822T PL3435980T3 PL 3435980 T3 PL3435980 T3 PL 3435980T3 PL 17729822 T PL17729822 T PL 17729822T PL 17729822 T PL17729822 T PL 17729822T PL 3435980 T3 PL3435980 T3 PL 3435980T3
- Authority
- PL
- Poland
- Prior art keywords
- fosnetupitant
- injectable formulations
- physiologically balanced
- balanced injectable
- physiologically
- Prior art date
Links
- HZIYEEMJNBKMJH-UHFFFAOYSA-N [4-[5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl]-methylamino]-4-(2-methylphenyl)pyridin-2-yl]-1-methylpiperazin-1-ium-1-yl]methyl hydrogen phosphate Chemical compound C=1N=C(N2CC[N+](C)(COP(O)([O-])=O)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HZIYEEMJNBKMJH-UHFFFAOYSA-N 0.000 title 1
- 229950010727 fosnetupitant Drugs 0.000 title 1
- 239000007972 injectable composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345942P | 2016-06-06 | 2016-06-06 | |
| EP17729822.1A EP3435980B1 (en) | 2016-06-06 | 2017-06-01 | Physiologically balanced injectable formulations of fosnetupitant |
| PCT/EP2017/063268 WO2017211663A1 (en) | 2016-06-06 | 2017-06-01 | Physiologically balanced injectable formulations of fosnetupitant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3435980T3 true PL3435980T3 (pl) | 2020-05-18 |
Family
ID=59055193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17729822T PL3435980T3 (pl) | 2016-06-06 | 2017-06-01 | Fizjologicznie zrównoważone preparaty fosnetupitantu do wstrzykiwania |
Country Status (36)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11654154B2 (en) | 2019-01-29 | 2023-05-23 | Navinta Iii Inc | Process for preparing injectable Fosaprepitant Dimeglumine compositions having improved storage stability |
| US12097197B2 (en) | 2021-12-21 | 2024-09-24 | Slayback Pharma Llc | Stable liquid compositions of netupitant and palonosetron |
| JP7783403B2 (ja) * | 2022-03-23 | 2025-12-09 | 大鵬薬品工業株式会社 | ホスネツピタント又はその医薬上許容される塩の安定化製剤およびその製造方法 |
| WO2025036703A1 (en) * | 2023-08-13 | 2025-02-20 | Helsinn Healthcare Sa | Fosnetupitant for administration via intravenous bolus |
| WO2025056094A1 (zh) * | 2023-09-15 | 2025-03-20 | 广州帝奇医药技术有限公司 | 一种冻干制剂和注射液及其制备方法 |
| CN119185243A (zh) * | 2024-11-28 | 2024-12-27 | 山东齐都药业有限公司 | 福奈妥匹坦帕洛诺司琼口服掩味颗粒剂及其制备方法与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| KR100286412B1 (ko) | 1993-12-29 | 2001-04-16 | 더블유. 지. 콜 | 치환된 모르폴린 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| JO2735B1 (en) * | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
| US20060167072A1 (en) * | 2004-01-30 | 2006-07-27 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
| US20100048607A1 (en) * | 2008-08-25 | 2010-02-25 | Chandrashekhar Kocherlakota | Formulations comprising palonosetron |
| US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| EP2866797B1 (en) * | 2012-07-06 | 2020-04-29 | Pharmathen S.A. | Stable injectable pharmaceutical composition of neurokinin 1 receptor antagonist and process for preparation thereof |
-
2017
- 2017-06-01 SG SG11201809708PA patent/SG11201809708PA/en unknown
- 2017-06-01 EP EP17729822.1A patent/EP3435980B1/en active Active
- 2017-06-01 KR KR1020187034943A patent/KR102459416B1/ko active Active
- 2017-06-01 WO PCT/EP2017/063268 patent/WO2017211663A1/en not_active Ceased
- 2017-06-01 LT LTEP17729822.1T patent/LT3435980T/lt unknown
- 2017-06-01 BR BR112018074655-0A patent/BR112018074655B1/pt active IP Right Grant
- 2017-06-01 MA MA44513A patent/MA44513B1/fr unknown
- 2017-06-01 MD MDE20190164T patent/MD3435980T2/ro unknown
- 2017-06-01 MX MX2018015036A patent/MX376118B/es active IP Right Grant
- 2017-06-01 EA EA201892837A patent/EA036605B1/ru unknown
- 2017-06-01 PH PH1/2018/502524A patent/PH12018502524B1/en unknown
- 2017-06-01 CN CN201780034681.5A patent/CN109310627B/zh active Active
- 2017-06-01 AU AU2017276588A patent/AU2017276588B2/en active Active
- 2017-06-01 JP JP2018563684A patent/JP6936817B2/ja active Active
- 2017-06-01 EP EP19200383.8A patent/EP3626231A1/en not_active Withdrawn
- 2017-06-01 ES ES17729822T patent/ES2771226T3/es active Active
- 2017-06-01 SI SI201730178T patent/SI3435980T1/sl unknown
- 2017-06-01 PL PL17729822T patent/PL3435980T3/pl unknown
- 2017-06-01 HR HRP20200196TT patent/HRP20200196T1/hr unknown
- 2017-06-01 PT PT177298221T patent/PT3435980T/pt unknown
- 2017-06-01 RS RS20200100A patent/RS59852B1/sr unknown
- 2017-06-01 DK DK17729822.1T patent/DK3435980T3/da active
- 2017-06-01 MY MYPI2018001970A patent/MY194081A/en unknown
- 2017-06-01 CA CA3025837A patent/CA3025837C/en active Active
- 2017-06-01 UA UAA201812842A patent/UA122285C2/uk unknown
- 2017-06-01 PE PE2018003074A patent/PE20190347A1/es unknown
- 2017-06-02 US US15/611,785 patent/US10624911B2/en active Active
- 2017-06-02 AR ARP170101521A patent/AR108676A1/es unknown
- 2017-06-02 UY UY0001037273A patent/UY37273A/es active IP Right Grant
- 2017-06-06 TW TW106118613A patent/TWI725191B/zh active
- 2017-06-06 JO JOP/2017/0137A patent/JOP20170137B1/ar active
-
2018
- 2018-11-09 CO CONC2018/0011686A patent/CO2018011686A2/es unknown
- 2018-11-19 IL IL263126A patent/IL263126B/en active IP Right Grant
- 2018-11-22 CL CL2018003338A patent/CL2018003338A1/es unknown
- 2018-11-23 ZA ZA2018/07932A patent/ZA201807932B/en unknown
-
2019
- 2019-01-02 EC ECSENADI2019169A patent/ECSP19000169A/es unknown
-
2020
- 2020-02-10 CY CY20201100123T patent/CY1122755T1/el unknown
- 2020-03-13 US US16/817,683 patent/US11529362B2/en active Active
-
2021
- 2021-08-27 JP JP2021138576A patent/JP7223084B2/ja active Active
-
2022
- 2022-11-15 US US17/986,934 patent/US12208109B2/en active Active
-
2024
- 2024-12-23 US US18/999,533 patent/US20250235473A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291163A (en) | Clinical formulations | |
| ZA201801035B (en) | Vaccine compositions | |
| IL246978A0 (en) | New paracetamol formulations | |
| SI4070788T1 (sl) | Farmacevtske formulacije | |
| IL256491A (en) | Pharmaceutical formulations | |
| ZA201807932B (en) | Physiologically balanced injectable formulations of fosnetupitant | |
| PL3474822T3 (pl) | Preparaty brincydofowiru | |
| IL262745A (en) | Improved preparations containing drugs | |
| IL256115A (en) | Pharmaceutical formulations of injectable lapmoline | |
| IL272857A (en) | Cofanalisib formulations | |
| IL248377B (en) | Formulations of lyophilized hgf | |
| ZA201707094B (en) | Pharmaceutical formulations | |
| IL267279A (en) | Pharmaceutical formulations of suvorexant | |
| PT3678644T (pt) | Formulações de copanlisib | |
| GB201609903D0 (en) | Therapeutic compositions | |
| GB201504482D0 (en) | Novel formulations | |
| GB201507784D0 (en) | Formulations | |
| GB201505532D0 (en) | Formulations |